Cognitive sequelae of cerebrovascular and gut dysfunction in post-acute COVID-19 syndrome.
急性后 COVID-19 综合征脑血管和肠道功能障碍的认知后遗症。
基本信息
- 批准号:10627220
- 负责人:
- 金额:$ 73.73万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-07-01 至 2028-05-31
- 项目状态:未结题
- 来源:
- 关键词:2019-nCoVACE2AcuteAdultAffectAreaAttentionAutopsyBindingBiological MarkersBrainBreath TestsCOVID-19COVID-19 impactCOVID-19 mortalityCOVID-19 pandemic effectsCOVID-19 patientCarbon DioxideCerebrovascular systemChronicClinicalCognitionCognition DisordersCognitiveCognitive deficitsColorDataDiseaseEncephalitisEndotheliumEndotoxinsEtiologyExtramural ActivitiesFunctional Magnetic Resonance ImagingFunctional disorderFundingGasesGastroenterologyGlial Fibrillary Acidic ProteinGrantHealthImpaired cognitionImpairmentIndividualInfectionInfiltrationInflammatoryInternal MedicineInterventionIntestinesLactuloseLeftLipopolysaccharidesLong COVIDMeasuresModelingNatureNeurobehavioral ManifestationsNeuropsychologyParticipantPathogenesisPathogenicityPathologicPathway interactionsPatientsPeptidoglycanPermeabilityPhasePhysiologicalPlasmaProliferatingRecording of previous eventsRecoveryReportingResearchResearch PersonnelRespirationRespiratory Signs and SymptomsRoleSARS-CoV-2 infectionShort-Term MemorySmooth Muscle MyocytesSolidStatistical Data InterpretationStructureSymptomsSystemTextTimeToxinVascular DiseasesViralVirusVisitWorkacronymsbrain fogcerebrovascularcerebrovascular imagingcytokinecytokine release syndromedysbiosisexecutive functionexperiencefatty acid-binding proteinsgastrointestinal systemgut dysbiosisgut healthgut microbiotagut-brain axisinnovationinter-institutionalinterestintestinal barrierintestinal epitheliummicrobiotamultidisciplinarymultimodal neuroimagingmultimodalityneuroimagingneuroinflammationneuropathologyneurotoxicneurovascularneurovascular unitnovelpersistent symptomprecision medicineprocessing speedpublic health emergencyreceptorrecruitsecondary analysiszonulin
项目摘要
ABSTRACT: Approximately one third of non-hospitalized coronavirus disease of 2019 (COVID-19) patients
report chronic symptoms after recovering from the acute stage of severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2) infection. Some of the most persistent and common complaints of this post-acute COVID-19
syndrome (PACS) are cognitive in nature, described subjectively as “brain fog” and also objectively measured
as deficits in executive function, working memory, attention, processing speed. The mechanisms of these chronic
cognitive sequelae are currently not understood. Most studies to-date have focused on direct SARS-CoV-2
infection of the brain; however, while direct viral brain infection is plausible in acute cases of severe and fatal
COVID-19, it is of interest to examine indirect mechanisms of chronic cognitive dysfunction that follow mild and
asymptomatic disease cases. SARS-CoV-2 inflicts damage to cerebral blood vessels and the intestinal wall by
binding to angiotensin-converting enzyme 2 (ACE2) receptors and also by producing high levels of systemic
cytokines, compromising the brain’s neurovascular unit and degrading the intestinal barrier, potentially increasing
the permeability of both to harmful substances. Such substances are hypothesized to be produced by pathogenic
microbiota in the gut that, given the profound effects COVID-19 has on the gastrointestinal system, may flourish
via intestinal dysbiosis. COVID-19 may therefore create a scenario in which neurotoxic and neuroinflammatory
substances readily proliferate from the gut lumen and encounter a weakened neurovascular unit, gaining access
to the brain and subsequently producing cognitive deficits. We intend to examine such effects of SARS-CoV-2
in PACS patients longitudinally over the course of 3 study visits (baseline, 4 months, and 8 months). The
impairments of cerebrovascular function and intestinal barrier, as well as their effects on cognitive
symptomology, will be examined in 80 former COVID-19 patients who recovered from non-hospitalized acute
phases of COVID-19, yet report persistent cognitive symptoms (PACS+). These patients will be compared with
80 former similar COVID-19 patients without such symptoms (PACS-). Forty healthy control participants will also
be recruited to establish general neurovascular, intestinal, and cognitive effects of COVID-19 history.
Cerebrovascular function will be quantified via innovative functional magnetic resonance imaging of
cerebrovascular reactivity (CVR) to respiration of CO2 gas, while the intestinal barrier will be assessed via
concentrations of intestinal wall biomarkers in blood plasma such as fatty acid-binding protein 2 (FABP-2) and
zonulin. Gut dysbiosis will be established via lactulose breath testing, and levels of subsequently produced and
systemically released lipopolysaccharide (LPS), peptidoglycan (PGN) and pro-inflammatory cytokines will also
be quantified. Impairments in the neurovascular unit and intestinal barrier in the context of gut dysbiosis are
expected to be associated with greater cognitive deficits in PACS+ patients. This work may reveal immediate
recourses for resolving PACS cognitive effects via existing treatments for vascular dysfunction and gut health.
摘要:约三分之一的2019年未住院的冠状病毒病(COVID-19)患者
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Andrei A Vakhtin其他文献
Andrei A Vakhtin的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似国自然基金
新型蝙蝠MERS簇冠状病毒HKU5的ACE2细胞受体识别及其分子机制研究
- 批准号:
- 批准年份:2024
- 资助金额:0.0 万元
- 项目类别:省市级项目
铁皮石斛通过肠道 ACE2 修复 Trp/GPR142 介
导“肠-胰岛 ”轴血糖调控功能的降糖机制研
究
- 批准号:Y24H280055
- 批准年份:2024
- 资助金额:0.0 万元
- 项目类别:省市级项目
人类ACE2变构抑制剂的成药性及其抗广谱冠状病毒感染的机制研究
- 批准号:82330111
- 批准年份:2023
- 资助金额:220 万元
- 项目类别:重点项目
CAFs来源的外泌体负性调控ACE2促进肾透明细胞癌癌栓新辅助靶向耐药的机制研究
- 批准号:82373169
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
新型蝙蝠MERS簇冠状病毒HKU5的ACE2受体识别及细胞入侵机制研究
- 批准号:32300137
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
基于AT2/ACE2/Ang(1-7)/MAS轴调控心脏-血管-血液系统性重构演变规律研究心衰气虚血瘀证及其益气通脉活血化瘀治法生物学基础
- 批准号:82305216
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
基于外泌体miRNAs介导细胞通讯的大豆ACE2激活肽调控血管稳态机制研究
- 批准号:32302080
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
感毒清经ACE2/Ang(1-7)/MasR信号通路抑制PM2.5诱导慢性气道炎症的机制:聚焦肺泡巨噬细胞极化与“胞葬”的表型串扰
- 批准号:82305171
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
刺参自溶引发机制中ACE2调控靶点的调控网络研究
- 批准号:32372399
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
Spike变异对新冠病毒抗原性及ACE2种属嗜性的影响研究
- 批准号:82272305
- 批准年份:2022
- 资助金额:52 万元
- 项目类别:面上项目
相似海外基金
新型コロナウイルス感染阻害能を有する抗ACE2抗体の阻害機構に関する構造基盤解明
阐明具有抑制新型冠状病毒感染能力的抗ACE2抗体抑制机制的结构基础
- 批准号:
24K09338 - 财政年份:2024
- 资助金额:
$ 73.73万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
ACE2のユビキチン化を介したコロナウイルス感染機構の解明と創薬への挑戦
通过ACE2泛素化阐明冠状病毒感染机制和药物发现的挑战
- 批准号:
22KJ2499 - 财政年份:2023
- 资助金额:
$ 73.73万 - 项目类别:
Grant-in-Aid for JSPS Fellows
ACE2阻害薬およびERK経路阻害薬による慢性腎炎進展抑制効果の検証
ACE2抑制剂和ERK通路抑制剂抑制慢性肾炎进展的效果验证
- 批准号:
23K14982 - 财政年份:2023
- 资助金额:
$ 73.73万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Large-scale compatibility assessments between ACE2 proteins and diverse sarbecovirus spikes
ACE2 蛋白和多种 sarbecovirus 尖峰之间的大规模兼容性评估
- 批准号:
10722852 - 财政年份:2023
- 资助金额:
$ 73.73万 - 项目类别:
一次線毛とコロナウイルス感染におけるACE2の役割の解明
阐明 ACE2 在原发菌毛和冠状病毒感染中的作用
- 批准号:
22KF0004 - 财政年份:2023
- 资助金额:
$ 73.73万 - 项目类别:
Grant-in-Aid for JSPS Fellows
The regulatory roles of ACE2 and its interaction with Nrf2 in arsenic-induced endothelial dysfunction in experimental and epidemiological studies
实验和流行病学研究中 ACE2 的调节作用及其与 Nrf2 的相互作用在砷诱导的内皮功能障碍中的作用
- 批准号:
23K16310 - 财政年份:2023
- 资助金额:
$ 73.73万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Role of ACE2 in the mechanism of intestinal regeneration
ACE2在肠道再生机制中的作用
- 批准号:
23K15078 - 财政年份:2023
- 资助金额:
$ 73.73万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Research and development of a novel pediatric anti-obesity medicine via ACE2 activation in DIZE
通过 DIZE 中 ACE2 激活研发新型儿科抗肥胖药物
- 批准号:
23K15417 - 财政年份:2023
- 资助金额:
$ 73.73万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Lung delivery of novel ACE2 variants for COVID-19
针对 COVID-19 的新型 ACE2 变体的肺部输送
- 批准号:
10483042 - 财政年份:2022
- 资助金额:
$ 73.73万 - 项目类别:
ACE2 on gut barrier dysfunction and BRB disruption
ACE2 对肠道屏障功能障碍和 BRB 破坏的影响
- 批准号:
10535485 - 财政年份:2022
- 资助金额:
$ 73.73万 - 项目类别:














{{item.name}}会员




